Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J7EB | ISIN: FR0011341205 | Ticker-Symbol: 5NR
Tradegate
06.06.25 | 12:14
4,010 Euro
-1,11 % -0,045
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NANOBIOTIX SA Chart 1 Jahr
5-Tage-Chart
NANOBIOTIX SA 5-Tage-Chart
RealtimeGeldBriefZeit
4,1554,17016:55
4,1554,17016:46

Aktuelle News zur NANOBIOTIX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
NANOBIOTIX Aktie jetzt für 0€ handeln
21.05.Nanobiotix S.A. reports Q1 results3
21.05.Nanobiotix S.A.: Nanobiotix Provides First Quarter 2025 Operational and Financial Update104Dosing of a first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial for patients with stage 3 unresectable non-small cell lung cancerPresentation of data at the European...
► Artikel lesen
21.05.Nanobiotix S.A. - 6-K, Report of foreign issuer1
14.05.Nanobiotix S.A. - S-8, Securities to be offered to employees in employee benefit plans2
14.05.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company1
12.05.Nanobiotix S.A. - 6-K, Report of foreign issuer1
05.05.Nanobiotix Reveals Favorable Results Of JNJ-1900 Study Pancreatic Cancer; Seeks Further Evaluation346NEW BRUNSWICK (dpa-AFX) - Nanobiotix S.A. (NBTX), a biotechnology company focused on nanoparticle-based cancer treatments, announced Monday positive full results from the completed dose escalation...
► Artikel lesen
05.05.Nanobiotix S.A.: Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer244Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancerMedian Overall Survival...
► Artikel lesen
30.04.Nanobiotix S.A. - 6-K, Report of foreign issuer1
14.04.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company2
10.04.Nanobiotix S.A. - 6-K, Report of foreign issuer2
04.04.Guggenheim cuts Nanobiotix stock target to $8, maintains buy5
02.04.Nanobiotix GAAP EPS of -€1.441
02.04.Nanobiotix S.A. - 20-F, Annual and transition report of foreign private issuers2
02.04.Nanobiotix S.A.: NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results118Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and...
► Artikel lesen
31.03.Nanobiotix S.A.: NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 20251
27.03.Nanobiotix reports promising NSCLC treatment study results1
27.03.Nanobiotix S.A. - 6-K, Report of foreign issuer1
27.03.Nanobiotix S.A.: Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC316Data show favorable safety and confirm injection feasibility in 12 patients with locally advanced NSCLC amenable to re-irradiation for whom prior lines of therapy have failedA preliminary review of...
► Artikel lesen
18.03.Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden3
Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1